Plandai Biotechnology Inc (OTCMKTS:PLPL) is a up and coming micro cap, and part of the health and wellness craze that’s all around us. Every outlet who sells food from McDonalds to the local 7–Eleven has healthy food choices. Nearly every menu is shifting from things that taste good to things that make you feel better.
It seems as though nearly all healthy lifestyle enthusiasts take some sort of powdered form of supplement in the morning to start their day, and Plandai is front and center in this lifestyle change. It’s all about science, chemistry and funding as supplements take a step higher as part of our diet. These are all good things for investors as this health lifestyle sector continues its march to higher levels.
It starting to feel like the big four now are cannabis, blockchain/bitcoin, digital media and healthy lifestyle stocks as these sectors mature and begin to break out.
Plandai Biotechnology Inc (OTCMKTS:PLPL) announced last week that its highly bioavailable Phytofare® Catechin Complex would be the active ingredient in Capital Brand’s reformulated and soon-to-be released SuperFood Fat Burning Boost®, which is used with the brand NutriBullet. Plandaí’s signature brand Phytofare® will make its way to the U.S. and Europe in Coyne Healthcare’s product Origine 8™.
Coyne Healthcare placed an order for 1.2 million of Plandaí’s Origine 8™ capsules, which is a product that uses bioavailable green tea extract, Phytofare® Catechin Complex, but further enhances the bioavailability of the extract by using an advanced liposome technology developed and clinically validated to improve the delivery of nutritional substances.
Subscribe below and we’ll keep you on top of what’s happening before $PLPL stock makes its next move.
Origine 8™ is a product that entraps all 8 of the catechins of the tea plant, and according to Plandaí, it is the only catechin-based capsule on the market backed by human clinical studies.
Coyne Healthcare has already been selling Plandaí’s unique product in South Africa, but it now expects to launch Origine 8™ this month in both the U.S. and Europe. The good news for Plandaí is that Coyne Healthcare has forecasted sales of 10.6 million Origine 8™ capsules in 2017, and Coyne expects sales to further increase to 24 million Origine 8™ capsules in 2018.
Coyne makes its products available through pharmacies, health food stores and medical practitioners, for both NutriBullet and Coyne Healthcare to bring Plandaí’s signature brand to the U.S.
The company also recently announced that it has executed an agreement with Cambridge Commodities Ltd. to become the exclusive Phytofare® distributor for the United Kingdom and all of Europe. Based in England, Cambridge Commodities specializes in supplying nutritional ingredients and finished products to the sports nutrition, health and well-being, pet and equine, and food industries.
Under the terms of the agreement, Cambridge Commodities will be required to meet specific quarterly sales goals to retain its exclusive distributor status with the initial quotas being established after a short ramp-up period.
Cambridge Commodities requires all suppliers to complete a verification process consisting of a meticulous questionnaire and thorough sampling of the material before approval. Their technical team, which includes nine professional lead auditors, travel to all parts of the world to ensure products meet all regulatory and quality requirements, and that those products adhere to environmental and social responsibility policies.
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, commented, “Cambridge Commodities has been a Plandaí customer for over a year, so they are very familiar with Phytofare®. When the opportunity for a new distributor opened up in the European territory, we all agreed that it would be a perfect partnership. Cambridge has excellent contacts throughout Europe, experienced sales reps, and a great training program. We’re confident that they will easily meet and exceed their sales quota and we look forward to working with them.”
Shares have done little for Plandaí Biotechnology (OTCMKTS:PLPL) moving sideways with sporadic volume as the news circulates through the markets. This company looks like it is organizing itself well operationally and is establishing a global footprint for sales, they are also hiring market awareness firms to get the word out about the product and the stock itself. These are all good signs, but the real test will be when shareholders come to buy the stock and need to make a decision between having this be a short term trade or a buy and hold.
We like what we see as this is a sneaky huge growth market for the millennial demographic where funding, sales and solid marketers can grab market share with proper branding. We will add this to our universe of stocks to watch as we have our morning coffee and shake! For more news on PLPL and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.
